Home
overview

SMi’s Biomarkers in Clinical Trials conference will present attendees with new concepts in biomarker application as well as a comprehensive review of recent developments. This unique event will bring together academics and industry professionals in order to provide a complete picture. There will be a strong focus on using biomarkers to bridge the gap between basic and applied research in drug development.

There will also be a half-day post-conference workshop on Commercialisation of Biomarkers for Personalised Medicine. This interactive event will use examples and case studies to present participants with the opportunity to deal with the problems that they face or expect to face when defining their own biomarker commercialisation strategies.

 

View the conference programme

 

Register for the event

 

Download a brochure

 

    RNAi 3         

 

Presentations will contain examples of biomarker application in the development of treatments for conditions in different therapeutic areas including oncology, nephrology, neurology and cardiology. Attendees will have the opportunity to network with industry associates and discuss the way forward in translational research and personalised medicine.

    

Hear case studies relating to the use of translational biomarkers

Identify ways of combining clinical, imaging and tissue biomarkers

Explore the potential of next-generation sequencing technologies

Discover the advantages of efficacy biomarkers in exploratory development

Discuss the potential of microRNA as a biomarker for drug efficacy 

           

 

Vice Presidents, Heads, Directors, Scientists and Project Leaders of:

 

  • Research and Development
  • Drug Safety Assessment
  • Biomarker Discovery/Validation
  • Diagnostics
  • Imaging
  • Clinical Pharmacology
  • Toxicology                                          

 

  • Experimental Medicine
  • Translational Medicine
  • Drug Metabolism
  • Pharmacokinetics
  • Clinical Pathology
  • Molecular and Cell Biology
  • Oncology                                              

Interested in speaking?
If you are interested in making a presentation at this or one of our other events, please contact our production department at smiproduction@smi-online.co.uk

Interested in sponsoring?
For sponsorship and exhibitioning opportunities,  contact our sponsorship team at sponsorshipdept@smi-online.co.uk

 

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Russell Petty

Russell Petty, Clinical Senior Lecturer in Medical Oncology, University of Aberdeen

9:10 Translational Biomarkers

Mark Fidock

Mark Fidock, Associate Director, Pfizer

  • Preclinical Biomarker discovery and translation for clinical utility
  • Biomarker tool box – enabling PK/PD
  • Case studies in the area of inflammation and infectious diseases
  • Biomarker use for decision making in clinical studies
  • 9:50 Using Preclinical Data to Optimise the Value of Biomarkers in the Clinic

    Chris Harbron

    Chris Harbron, Technical Lead Statistician, Discovery Statistics, AstraZeneca

  • Using molecular biomarkers to identify patient populations
  • The use of preclinical data from in-vitro systems and samples from undosed volunteers
  • Increasing the likelihood of robust identification of patients who would benefit from treatment
  • Reproducibility, robustness, evaluability, translation and interpretability
  • Implications for clinical development processes
  • 10:30 Morning Coffee

    10:50 Delivering on the Promise of Personalised Healthcare – Lessons from AstraZeneca

    Ansar Jawaid

    Ansar Jawaid, Global Diagnostics Manager, AstraZeneca

  • Overview of personalised healthcare
  • Challenges across the value chain
  • Leanings from AstraZeneca case studies
  • 11:30 Translating Biomarkers into Companion Diagnostics

    Hannah Mamuszka

    Hannah Mamuszka, Strategic Business Development Manager, Asuragen

  • Drug and diagnostic co-development – key drivers
  • Lessons learned in companion diagnostic development
  • Companion diagnostic development models
  • IVD and clinical trial assays
  • 12:10 Using LNA™ technology to transform novel biomarker discovery into effective Companion Diagnostics

    Adam Baker

    Adam Baker, Director of Diagnostic Product Development, Exiqon

  • Using a Locked Nucleic Acid (LNA™) based miRNA detection technology we have developed a high throughput QPCR system
  • Validated system for the detection of miRNAs in clinical paraffin-embedded tissue as well as blood derived plasma or serum
  • Use of the LNA™ bases adds critical specificity and sensitivity
  • Robust system for more rapid assay development in the clinical and diagnostic assay development
  • 12:50 Networking Lunch

    13:50 Translating Lymphoma Gene Expression Signatures into Routine Clinical Biomarkers

    Alison Banham

    Alison Banham, Senior Scientist, Nuffield Department of Clinical Laboratory Sciences, University of Oxford

  • Identification of patients who are not responsive to current therapy
  • The need for co-development of biomarkers and novel therapies
  • Reassessment of biomarker utility in response to evolving gold standard therapy
  • The importance of reagents and techniques that enable specific and reproducible biomarker detection
  • 14:30 Use of Academic Laboratories in Clinical Trials to Foster Collaborative Biomarker Research

    Mike Lau

    Mike Lau, Principal Clinical Development Scientist, Oncology, GlaxoSmithKline

  • Use of biomarkers in clinical research
  • Outsourcing to commercial laboratories
  • Collaborations with academic laboratories in clinical research
  • Case study/example in oncology trials
  • 15:10 Automating Biomarker Discovery and Qualification – Capturing Hypothesis, Analysis and Intellectual Property

    Robin Munro

    Robin Munro, Principal Consultant, IDBS

  • Solutions to empower scientists to seamlessly use and integrate clinical, genomic and image data
  • Automatically annotating genomic data using internal, public and third party sources
  • Using E-WorkBook: steps and decision points of the experimental set-up, data capture and analysis
  • Reports can be automatically generated and the burden of validation reduced
  • 15:50 Afternoon Tea

    16:10 Multimodality Cancer Biomarker Discovery and Development: Optimising the use of Biospecimens and Patients

    Russell Petty

    Russell Petty, Clinical Senior Lecturer in Medical Oncology, University of Aberdeen

  • Complex clinical phenotypes in cancer patients
  • Combining clinical, imaging and tissue biomarkers
  • Combined hypothesis generating and hypothesis driven approaches
  • Clinical implementation of combined biomarker modality approaches
  • 16:50 Biomarkers in Muscular Disease: A Turning Point for Innovative Therapy Monitoring

    Alessandra Ferlini

    Alessandra Ferlini, Associate Professor, University of Ferrara

  • Muscular dystrophies
  • Molecular therapies
  • OMIC biomarkers
  • Biomarkers discovery by selecting sub-phenotypes
  • 17:30 Chairman's Closing Remarks & Close of Day One

    8:30 Re-registration & Coffee

    9:00 Chairman's Opening Remarks

    Dominic Williams

    Dominic Williams, Senior Lecturer, MRC Centre for Drug Safety Science, University of Liverpool

    9:10 The Advantages of Efficacy Biomarkers in Exploratory Development

    Shethah Morgan

    Shethah Morgan, Senior Research Clinical Scientist, Oncology Clinical Biomarker Group, AstraZeneca

  • Determining which efficacy biomarkers are appropriate
  • Validation of Phase I efficacy biomarkers
  • Assessing whether a drug is on target
  • Regulatory authorities and efficacy biomarkers
  • 9:50 Translational Biomarkers in Drug Induced Liver Injury

    Dominic Williams

    Dominic Williams, Senior Lecturer, MRC Centre for Drug Safety Science, University of Liverpool

  • Role of metabolism in drug-induced liver injury
  • Mechanistic biomarkers of cell damage
  • Involvement of the innate immune system during hepatic stress
  • A chronic infusion model of paracetamol hepatotoxicity
  • 10:30 An Overview of Next-Generation Sequencing Technologies

    David Dow

    David Dow, Group Leader, Molecular and Cellular Technologies, GlaxoSmithKline

  • Technology overview
  • Recent advances
  • Potential applications in biomarker research
  • Future developments
  • 11:10 Morning Coffee

    11:30 MicroRNA as Biomarkers of Disease and Drug Efficacy

    Sterghios Moschos

    Sterghios Moschos, Principle Scientist, Pfizer

  • Introduction to microRNAs
  • Approaches and considerations in microRNA profiling for biomarker discovery
  • Clinical progress of microRNA biomarker assays
  • Emerging evidence on invasive and non-invasive microRNA signature utility in diagnostics and theranostics
  • 12:10 Miniaturised Multiplexed Immunoassays

    Thomas Joos

    Thomas Joos, Head of Biochemistry, Natural and Medical Sciences Institute, Universitat Tubingen

  • Technologies and applications
  • Capabilities and limitations of multiplexed immunoassays
  • Multiplexed immunoassays for biomarker discovery
  • 12:50 Networking Lunch

    14:00 Innovative and New Ways of Conducting Clinical Trials in Biomarkers

    Shawnmarie Mayrand-Chung

    Shawnmarie Mayrand-Chung, NIH Director for the Biomarkers Consortium, National Institutes of Health

  • Navigating the landscape to design and conduct effective, efficient and regulatory acceptable trials
  • Biomarkers and adaptive trial designs: shortening the time it takes to discover and prove that a new drug or medical procedure is effective
  • Modelling and monitoring the effectiveness of personalised treatment in real time
  • Safety biomarkers: collaborative efforts for moving forward at a faster pace
  • 14:40 Applications of Nanoparticles for Biomarker Harvesting and Sensing

    Alan Dalton

    Alan Dalton, Senior Lecturer, Faculty of Engineering and Physical Sciences, University of Surrey

  • Engineering strategies to tailor nanoparticles for selective sequestering of biomarkers
  • High sensitivity proteomic tests
  • Competing with existing “state of the art” technology
  • Novel lab-on-a-chip type detection platforms
  • 15:20 Afternoon Tea

    15:40 Cancer Genetics-Guided Discovery of Serum Biomarkers

    Ralph Schiess

    Ralph Schiess, Co-Founder, ProteoMediX

  • Quantitative proteomics based biomarker discovery using model systems
  • Biomarker validation by highly sensitive targeted proteomics
  • PTEN tumor suppressor gene inactivation in prostate cancer
  • Protein biomarker for prostate cancer patient stratification
  • 16:20 Epigenetic Profiling for Patient Stratification

    Mark Eccleston

    Mark Eccleston, Managing Director, OncoLytika

  • Chromatin Structure and Gene Expression
  • Nucleosomics: Histone modification profiling
  • HyperGenomics: Nuclease accessible Site Profiling
  • Patient stratification and monitoring
  • 17:00 Chairman's Closing Remarks & Close of Conference

    +

    Workshops

    Commercialisation of Biomarkers for Personalised Medicine
    Workshop

    Commercialisation of Biomarkers for Personalised Medicine

    Hilton London Kensington
    22nd September 2010
    London, United Kingdom

    Hilton London Kensington

    179-199 Holland Park Avenue
    London W11 4UL
    United Kingdom

    Hilton London Kensington

    Expect a warm welcome the moment you arrive at Hilton London Kensington. We’re located in the leafy district of Holland Park, 30 minutes from Heathrow Airport, with excellent transport links into Central London and three different tube lines nearby. Step inside the hotel and you’ll find stylish rooms and suites, fantastic dining and first-class facilities for business and recreation — everything you need for a remarkable stay in the capital.

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.